| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
West Nile virus (WNV) NS2B‑NS3 serine protease. The peptide contains a specific cleavage sequence for this viral protease. The aromatic amino acids flanking the scissile bond contribute to substrate recognition.
|
|---|---|
| ln Vitro |
In cell‑free assays, this peptide acts as a substrate for the WNV NS2B‑NS3 protease. The protease cleaves the peptide, separating the fluorophore from the quencher, which results in an increase in fluorescence. This signal is directly proportional to the protease activity, allowing for the quantification of enzyme kinetics and inhibitor potency.
|
| Enzyme Assay |
A general cell‑free protocol for assessing protease activity: The WNV NS2B‑NS3 protease is pre‑incubated with varying concentrations of a potential inhibitor in a reaction buffer. The fluorogenic peptide substrate (Abz‑Gly‑Leu‑Lys‑Arg‑Gly‑Gly‑3‑(NO2)Tyr acetate) is then added to initiate the reaction. The increase in fluorescence (excitation 320 nm, emission 420 nm) is monitored continuously at 37degC for 30‑60 minutes. The initial rate of the reaction is calculated, and the IC50 of the inhibitor is determined.
|
| Cell Assay |
A general cellular protocol for assessing antiviral activity is not applicable for the peptide itself. The peptide is a biochemical tool, not a therapeutic agent. For drug discovery, the WNV protease inhibitor (identified through screening with this peptide) would be tested in cell‑based viral replication assays.
|
| Animal Protocol |
A general animal protocol for a WNV protease inhibitor (not the peptide substrate) would involve a mouse model of WNV infection. A mouse would be infected with WNV, and the candidate inhibitor would be administered at specific doses. Survival, viral load, and clinical signs would be monitored. However, this protocol is not used for the substrate peptide itself.
|
| ADME/Pharmacokinetics |
General PK protocol for the substrate peptide is not applicable. This peptide is a research reagent and is not used as a drug. It is not intended for in vivo administration.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for the peptide is not applicable. The peptide is not used in animals. It is a non-toxic biochemical tool for in vitro experimentation.
|
| References | |
| Additional Infomation |
Abz-Gly-Leu-Lys-Arg-Gly-Gly-3-(NO2)Tyr acetate has the molecular formula C40H₅₉N13O12 and a molecular weight of 913.98 g/mol (free base). The Abz group (o‑aminobenzoic acid) serves as the fluorophore, and the 3‑(NO2)Tyr (3‑nitrotyrosine) acts as the fluorescence quencher. The peptide is an acetate salt. It is a valuable tool for high‑throughput screening of WNV protease inhibitors and for detailed kinetic studies of the enzyme. The product is stored as a solid at -80degC.
|
| Molecular Formula |
C40H59N13O12.XC2H4O2
|
|---|---|
| Molecular Weight |
913.98 (free base)
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
